CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 62 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05712967
NCT05712967N/ACompleted

Role of the Host Microbiota and Il-17 in Favoring Multiple Myeloma Progression

IRCCS San Raffaele·observational·Posted Feb 6, 2023·Updated Mar 1, 2024

In Brief

An observational study for Multiple Myeloma. Completed, enrolled 62 participants across 1 site.

Detailed Summary

Goal of this observational, non-interventional study is to demonstrate that in humans a correlation exists between bone marrow (BM) levels of the cytokine interleukin 17 (IL-17) and composition of the gut microbiota in patients affected by smoldering multiple myeloma (SMM) or multiple myeloma (MM). Enrolled SMM/MM patients will be analyzed for their bone marrow levels of IL-17 together with the distribution of T helper 17 lymphocytes in their BM and peripheral blood. These analyses will be correlated with analyses of the patients' gut microbiome to identify commensal bacteria potentially involved in Th17 cell expansion.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedFeb 6, 2023
Enrollment StartJun 14, 2019
Primary CompletionFeb 5, 2024
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 3.4 years ago